Arbutus Interest Income from 2010 to 2026

ABUS Stock

USD 4.13 0.01 0.24%

Arbutus Biopharma Interest Income yearly trend continues to be comparatively stable with very little volatility. Interest Income will likely drop to about 3.9 M in 2026. Interest Income is income earned from the investment of cash or from lending money to others, including interest from bank accounts, bonds, or other interest-bearing investments. View All Fundamentals

Interest Income

First Reported

2019-03-31

Previous Quarter

1 M

Current Value

952 K

Quarterly Volatility

875.7 K

Covid

Interest Hikes

Check Arbutus Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Arbutus Biopharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.4 M, Interest Expense of 149.7 K or Selling General Administrative of 26.7 M, as well as many indicators such as Price To Sales Ratio of 92.94, Dividend Yield of 0.0424 or PTB Ratio of 7.98. Arbutus financial statements analysis is a perfect complement when working with Arbutus Biopharma Valuation or Volatility modules.

Build AI portfolio with Arbutus Stock

Check out the analysis of Arbutus Biopharma Correlation against competitors.

The evolution of Interest Income for Arbutus Biopharma Corp provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Arbutus Biopharma compares to historical norms and industry peers.

Latest Arbutus Biopharma's Interest Income Growth Pattern

Below is the plot of the Interest Income of Arbutus Biopharma Corp over the last few years. It is income earned from the investment of cash or from lending money to others, including interest from bank accounts, bonds, or other interest-bearing investments. Arbutus Biopharma's Interest Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Arbutus Biopharma's overall financial position and show how it may be relating to other accounts over time.

Interest Income

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Interest Income

Timeline

Arbutus Interest Income Regression Statistics

	Arithmetic Mean	11,025,601
	Geometric Mean	4,955,438
	Coefficient Of Variation	103.08
	Mean Deviation	10,419,105
	Median	5,166,000
	Standard Deviation	11,365,171
	Sample Variance	129.2T
	Range	25.7M
	R-Value	(0.77)
	Mean Square Error	56.7T
	R-Squared	0.59
	Significance	0.0003
	Slope	(1,726,796)
	Total Sum of Squares	2066.7T

Arbutus Interest Income History

	2026	3.9 M
	2025	5.9 M
	2024	6.6 M
	2023	5.2 M
	2022	2.2 M
	2021	127 K
	2020	741 K

Other Fundumenentals of Arbutus Biopharma Corp

Net Interest Income

Arbutus Biopharma Interest Income component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Net Receivables	Short Term Investments	Total Liab	Total Current Assets	Intangible Assets	Common Stock	Short Term Debt	Net Tangible Assets	Accounts Payable	Long Term Debt	Deferred Long Term Liab	Long Term Investments	Short Long Term Debt	Property Plant Equipment	Current Deferred Revenue	Capital Surpluse	Accumulated Depreciation	Long Term Debt Total	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		1.0	-0.75	0.0	-0.11	0.1	0.97	0.71	0.97	-0.21	0.63	0.9	0.41	0.04	0.96	0.22	0.41	0.19	-0.14	-0.01	-0.07	0.09	0.14	0.08	-0.09
Total Stockholder Equity	1.0		-0.76	0.01	-0.11	0.08	0.95	0.7	0.96	-0.23	0.62	0.89	0.4	0.04	0.95	0.24	0.4	0.21	-0.16	-0.03	-0.08	0.09	0.15	0.11	-0.1
Net Debt	-0.75	-0.76		-0.24	-0.09	0.36	-0.67	-0.49	-0.72	0.24	-0.43	-0.71	0.02	0.33	-0.75	-0.28	-0.27	0.18	0.19	0.22	0.1	-0.1	-0.24	-0.23	0.16
Retained Earnings	0.0	0.01	-0.24		-0.18	-0.83	-0.04	-0.55	0.05	0.09	0.35	-0.03	-0.69	-0.91	0.13	-0.21	-0.63	-0.52	-0.69	-0.95	-0.35	0.33	0.39	-0.19	-0.79
Net Receivables	-0.11	-0.11	-0.09	-0.18		0.05	-0.08	0.1	-0.09	-0.03	-0.24	-0.03	-0.16	-0.09	-0.07	-0.11	-0.06	-0.28	0.33	0.24	0.33	-0.17	-0.04	0.0	0.39
Short Term Investments	0.1	0.08	0.36	-0.83	0.05		0.15	0.56	-0.01	-0.2	-0.08	0.12	0.78	0.88	-0.06	0.15	0.68	0.59	0.56	0.76	0.35	-0.36	-0.26	0.08	0.6
Total Liab	0.97	0.95	-0.67	-0.04	-0.08	0.15		0.69	0.97	-0.17	0.65	0.89	0.4	0.05	0.96	0.14	0.41	0.14	-0.08	0.02	-0.04	0.06	0.11	-0.01	-0.03
Total Current Assets	0.71	0.7	-0.49	-0.55	0.1	0.56	0.69		0.58	-0.38	0.3	0.63	0.74	0.54	0.54	0.45	0.79	0.45	0.41	0.55	0.1	0.05	-0.04	0.25	0.37
Intangible Assets	0.97	0.96	-0.72	0.05	-0.09	-0.01	0.97	0.58		-0.13	0.59	0.87	0.3	-0.05	0.99	0.06	0.29	0.08	-0.22	-0.05	-0.04	0.07	0.07	-0.02	-0.09
Common Stock	-0.21	-0.23	0.24	0.09	-0.03	-0.2	-0.17	-0.38	-0.13		-0.24	-0.15	-0.23	-0.18	-0.13	-0.12	-0.41	-0.16	-0.04	-0.1	0.01	0.0	0.1	0.02	-0.02
Short Term Debt	0.63	0.62	-0.43	0.35	-0.24	-0.08	0.65	0.3	0.59	-0.24		0.57	-0.08	-0.14	0.61	-0.19	0.12	0.16	-0.52	-0.43	-0.19	0.18	0.34	-0.09	-0.43
Net Tangible Assets	0.9	0.89	-0.71	-0.03	-0.03	0.12	0.89	0.63	0.87	-0.15	0.57		0.32	-0.03	0.87	0.22	0.39	-0.04	-0.06	0.03	0.13	-0.13	0.44	0.28	0.15
Accounts Payable	0.41	0.4	0.02	-0.69	-0.16	0.78	0.4	0.74	0.3	-0.23	-0.08	0.32		0.75	0.25	0.49	0.64	0.52	0.51	0.67	0.08	-0.04	-0.23	0.23	0.42
Long Term Debt	0.04	0.04	0.33	-0.91	-0.09	0.88	0.05	0.54	-0.05	-0.18	-0.14	-0.03	0.75		-0.14	0.18	0.64	0.78	0.48	0.81	0.21	-0.21	-0.43	0.11	0.53
Deferred Long Term Liab	0.96	0.95	-0.75	0.13	-0.07	-0.06	0.96	0.54	0.99	-0.13	0.61	0.87	0.25	-0.14		0.05	0.26	0.0	-0.26	-0.13	-0.06	0.06	0.11	-0.03	-0.14
Long Term Investments	0.22	0.24	-0.28	-0.21	-0.11	0.15	0.14	0.45	0.06	-0.12	-0.19	0.22	0.49	0.18	0.05		0.25	0.06	0.55	0.25	-0.22	0.22	0.28	0.47	0.12
Short Long Term Debt	0.41	0.4	-0.27	-0.63	-0.06	0.68	0.41	0.79	0.29	-0.41	0.12	0.39	0.64	0.64	0.26	0.25		0.47	0.37	0.56	0.29	-0.3	-0.27	0.13	0.43
Property Plant Equipment	0.19	0.21	0.18	-0.52	-0.28	0.59	0.14	0.45	0.08	-0.16	0.16	-0.04	0.52	0.78	0.0	0.06	0.47		0.08	0.42	0.01	0.03	-0.4	-0.08	0.05
Current Deferred Revenue	-0.14	-0.16	0.19	-0.69	0.33	0.56	-0.08	0.41	-0.22	-0.04	-0.52	-0.06	0.51	0.48	-0.26	0.55	0.37	0.08		0.77	0.16	-0.06	-0.09	0.16	0.69
Capital Surpluse	-0.01	-0.03	0.22	-0.95	0.24	0.76	0.02	0.55	-0.05	-0.1	-0.43	0.03	0.67	0.81	-0.13	0.25	0.56	0.42	0.77		0.43	-0.26	-0.33	0.22	0.88
Accumulated Depreciation	-0.07	-0.08	0.1	-0.35	0.33	0.35	-0.04	0.1	-0.04	0.01	-0.19	0.13	0.08	0.21	-0.06	-0.22	0.29	0.01	0.16	0.43		-0.8	-0.03	0.33	0.68
Long Term Debt Total	0.09	0.09	-0.1	0.33	-0.17	-0.36	0.06	0.05	0.07	0.0	0.18	-0.13	-0.04	-0.21	0.06	0.22	-0.3	0.03	-0.06	-0.26	-0.8		0.07	-0.32	-0.52
Net Invested Capital	0.14	0.15	-0.24	0.39	-0.04	-0.26	0.11	-0.04	0.07	0.1	0.34	0.44	-0.23	-0.43	0.11	0.28	-0.27	-0.4	-0.09	-0.33	-0.03	0.07		0.49	-0.04
Net Working Capital	0.08	0.11	-0.23	-0.19	0.0	0.08	-0.01	0.25	-0.02	0.02	-0.09	0.28	0.23	0.11	-0.03	0.47	0.13	-0.08	0.16	0.22	0.33	-0.32	0.49		0.4
Capital Stock	-0.09	-0.1	0.16	-0.79	0.39	0.6	-0.03	0.37	-0.09	-0.02	-0.43	0.15	0.42	0.53	-0.14	0.12	0.43	0.05	0.69	0.88	0.68	-0.52	-0.04	0.4

Click cells to compare fundamentals

About Arbutus Biopharma Financial Statements

Arbutus Biopharma shareholders use historical fundamental indicators, such as Interest Income, to determine how well the company is positioned to perform in the future. Although Arbutus Biopharma investors may analyze each financial statement separately, they are all interrelated. The changes in Arbutus Biopharma's assets and liabilities, for example, are also reflected in the revenues and expenses on on Arbutus Biopharma's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

	Last Reported	Projected for Next Year
Interest Income	5.9 M	3.9 M
Net Interest Income	7.4 M	7.8 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Arbutus Stock Analysis

When running Arbutus Biopharma's price analysis, check to measure Arbutus Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arbutus Biopharma is operating at the current time. Most of Arbutus Biopharma's value examination focuses on studying past and present price action to predict the probability of Arbutus Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arbutus Biopharma's price. Additionally, you may evaluate how the addition of Arbutus Biopharma to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2026 Macroaxis LLC

Arbutus Interest Income from 2010 to 2026

Latest Arbutus Biopharma's Interest Income Growth Pattern

Arbutus Interest Income Regression Statistics

Arbutus Interest Income History

Other Fundumenentals of Arbutus Biopharma Corp

Arbutus Biopharma Interest Income component correlations

About Arbutus Biopharma Financial Statements

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Arbutus Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY